Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS)

The Lancet Infectious Diseases

Volumn 15, Issue 4, 2015, Pages 397-404

  Bourlière, Marc ^a   Bronowicki, Jean Pierre ^b   de Ledinghen, Victor ^c   Hézode, Christophe ^d   Zoulim, Fabien ^e   Mathurin, Philippe ^f   Tran, Albert ^g   Larrey, Dominique G ^h   Ratziu, Vlad ⁱ   Alric, Laurent ^j   Hyland, Robert H ^k   Jiang, Deyuan ^k   Doehle, Brian ^k   Pang, Phillip S ^k   Symonds, William T ^k   Subramanian, G Mani ^k   McHutchison, John G ^k   Marcellin, Patrick ^l   Habersetzer, François ^m   Guyader, Dominique ⁿ   Grangé, Jean Didier ^o   Loustaud Ratti, Véronique ^p   Serfaty, Lawrence ^q   Metivier, Sophie ^r   Leroy, Vincent ^s   Abergel, Armand ^t   Pol, Stanislas ^u   more..

^a HÔPITAL SAINT JOSEPH   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

^h HÔPITAL SAINT ELOI   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j UMR 152 IRD Universite Paul Sabatier   (France)

^k GILEAD SCIENCES   (United States)

^l BEAUJON HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁿ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^o HÔPITAL TENON   (France)

^p UNIVERSITY OF LIMOGES   (France)

^q HÔPITAL SAINT ANTOINE   (France)

^r CHU PURPAN   (France)

^s GRENOBLE UNIVERSITY HOSPITAL   (France)

^t UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^u UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; FALDAPREVIR; HEMOGLOBIN; LEDIPASVIR; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE; VIRUS RNA;

ADULT; ALLELE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BRONCHITIS; CHILD TURCOTTE PUGH SCORE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; IRRITABILITY; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; FRANCE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; FEMALE; FLUORENES; FRANCE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLACEBOS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD; YOUNG ADULT;

EID: 84925362379     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70050-2     Document Type: Article

References (21)

1. Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010, 8:924-933.
2. Poynard T, Afdhal NH Perspectives on fibrosis progression in hepatitis C: an à la carte approach to risk factors and staging of fibrosis. Antivir Ther 2010, 15:281-291.
3. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147:677-684.
4. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis: a 12-year prospective follow-up study. Hepatology 2010, 51:2069-2076.
5. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schonfeld PS A sustained virologic response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8:280-288.
6. Ng V, Saab S Effects of sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011, 9:923-930.
7. Vierling JM, Zeuzem S, Poordad F, et al. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol 2014, 61:200-209.
8. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013, 58:1918-1929.
9. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014, 147:132-142.
10. Colombo M, Strasser SI, Moreno C, et al. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: The International Telaprevir Access Program. J Hepatol 2014, 61:976-983.
11. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013, 59:434-441.
12. Bourlière M, Khaloun A, Wartelle-Bladou C, et al. Future treatment of patients with HCV cirrhosis. Liver Int 2012, 32(suppl 1):113-119.
13. Prescribing information Gilead Sciences, (accessed Feb 18, 2015). http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.
14. Lawitz E, Poordad F, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014, 383:515-523.
15. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
16. Kohli A, Shaffer A, Sherman A, Kottilil Shyam Treatment of hepatitis C: a systematic review. JAMA 2014, 312:631-640.
17. Sulkowski M, Gardiner DF, Rodriguez-Torres, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221.
18. Poordad F, Hezode C, Trihn R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
19. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
20. Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real-world experience from HCV-TARGET. J Hepatol 2015, 62:286-293.
21. Recommendations for testing, managing, and treating hepatitis C AASLD, IDSAIDSA, IAS-USAIAS-USA, (accessed Oct 23, 2014). http://www.hcvguidelines.org.